Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;91(1):13-24.
doi: 10.1007/s00280-022-04486-4. Epub 2022 Nov 4.

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

Marie Toukam  1 , Jens Wuerthner  2 , Karin Havenith  3 , Mehdi Hamadani  4 , Paolo F Caimi  5 , Tim Kopotsha  3 , Hans G Cruz  2 , Joseph P Boni  6
Affiliations

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

Marie Toukam et al. Cancer Chemother Pharmacol. 2023 Jan.

Abstract

Purpose: The objective of this analysis was to develop a population pharmacokinetic (PPK) model to characterize camidanlumab tesirine (Cami) pharmacokinetics based on the phase 1 study in relapsed/refractory lymphoma (NCT02432235).

Methods: An initial PPK model was developed based on a two-compartment model with parallel linear and nonlinear elimination pathways. Pharmacokinetic parameters were evaluated for correlation with potential demographic covariates; significant covariates were retained in the final model.

Results: In the final PPK model, baseline weight effects were included on clearance (CL), intercompartmental clearance (Q), and the volumes of distribution in the central (V1) and peripheral (V2) compartments. The baseline soluble CD25 (sCD25) effect was included on CL and maximum velocity of saturable clearance (Vmax); sex effect was included on CL and V1; and ethnicity effect was included on deconjugation clearance (CLdec). For a typical patient, CL and CLdec were 0.516 and 0.21 L/day, respectively (tAb elimination half-life: 18.72 days); V1 and V2 were 4.41 and 2.67 L, respectively; Vmax was 0.49 mg/day; the Michaelis-Menten constant (Km) was 0.409 µg/mL; and the first-order rate for decrease of Vmax (KDES) was 0.0197/day. Cami exposure was higher for patients with low baseline sCD25, higher body weight, and females.

Conclusions: The final model described the observed data well, estimates of PK parameters were obtained, and covariates with significant effects on Cami exposure were identified. Altogether, this final PPK model provides a robust basis for analysis of Cami exposure-response relationships and further supports identification of the optimal Cami dosing schedule for patients with relapsed/refractory lymphoma.

Keywords: ADCT-301; Antibody-drug conjugate; CD25; Camidanlumab tesirine; Phase 1; Pyrrolobenzodiazepine dimer.

PubMed Disclaimer

References

    1. Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol 10:239–249. https://doi.org/10.1080/17474086.2017.1281122 - DOI
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390. https://doi.org/10.1182/blood-2016-01-643569 - DOI
    1. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS (2015) Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 90:790–795. https://doi.org/10.1002/ajh.24086 - DOI
    1. Kaseb H, Babiker HM (2021) Hodgkin lymphoma. In: Statpearls. StatPearls Publishing. StatPearls Publishing LLC., Treasure Island
    1. LaCasce AS (2019) Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. Hematol Oncol 37(Suppl 1):87–91. https://doi.org/10.1002/hon.2589 - DOI

Publication types

Associated data

LinkOut - more resources